CTRI/2022/11/047636
招募中
4 期
A Phase IV interventional post approval trial to investigate effectiveness and safety of vericiguat therapy in Indian patients with chronic heart failure with reduced ejection fraction after a worsening heart failure event. - VERINA
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: I508- Other heart failure
- 发起方
- Bayer Zydus Pharma Private Limited
- 状态
- 招募中
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Male or female participants aged \>\=18 years at the time point of signing informed consent form (ICF).
- •2\. Has a history of chronic HF (NYHA class II\-IV) on standard therapy before qualifying HF decompensation.
- •3\. Has chronic HF with reduced LVEF ( \<45%) after a WHF event (defined as HF hospitalization or use of iv diuretics for HF \[without hospitalization]).
- •4\. Is capable of giving signed ICF and willing to comply with the study\-related procedures.
- •5\. Female participants in the following categories:
- •5\.1 A female who is not of reproductive potential, defined as a female who either: (a) is postmenopausal (defined as at least 12 months with no menses in women \>\=45 years of age); (b) has had a hysterectomy and/or bilateral oophorectomy,
- •bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to Screening; or (c) has a congenital or acquired condition that prevents childbearing
- •5\.2\. A female who is of reproductive potential and agrees to avoid becoming pregnant while receiving the study drug and for 14 days after the last dose of the study drug by complying with one of the following: (a) practice abstinence from
- •heterosexual activity or (b) use (and have her partner use) highly effective contraception method during heterosexual activity.
排除标准
- •1\. Participants who are clinically unstable at the time of screening defined by administration of any iv treatment within 24 hours until start of study intervention, and/or systolic blood pressure (SBP) \< 100 mmHg or symptomatic hypotension
- •2\. Participation in another interventional clinical study and treatment with another
- •investigational product \<\=30 days prior to screening
- •3\. Concurrent use of phosphodiesterase type 5 (PDE5\) inhibitors, or a soluble guanylate
- •cyclase (sGC) stimulator, such as riociguat
- •4\. Known allergy or hypersensitivity to any sGC stimulator
- •5\. Severe hepatic insufficiency such as with hepatic encephalopathy
- •6\. Severe renal impairment with eGFR \< 15 mL/min/1\.73m2(calculated based on the
- •Modification of Diet in Renal Disease \[MDRD] equation) or on dialysis
- •7\. Is pregnant or breast feeding or plans to become pregnant or to breastfeed during the
结局指标
主要结局
未指定
相似试验
招募中
4 期
A clinical trial to evaluate aflibercept treatment in patients with diabetic macular edema.Health Condition 1: H353- Degeneration of macula and posterior poleCTRI/2022/08/044792Bayer Zydus Pharma Private Limited
进行中（未招募）
1 期
Study comparing Treatment with Alluzience vs Reconstituted toxin (STAR)Moderate to severe glabellar lines (GL).MedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858Therapeutic area: Not possible to specifyEUCTR2021-004748-62-DEQ-Med AB, part of the Galderma Group150
进行中（未招募）
不适用
Study about the high flow and conventional oxigen therapy in patients with severe acute respiratory failure.EUCTR2012-001671-36-ESFundación para la Investigación Biomédica
招募中
3 期
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant studyRelapsed or refractory CD20 positive diffuse large B-cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12606000373572Roche40
招募中
4 期
Phase IV Efficacy Study of MMR Vaccine in Preventing or Reduction of Severity of COVID-19 in Healthcare Workers AdultsRBR-2xd6dkjniversidade Federal de Santa Catarina